(Q52925512)

9 May 2018

title

Bortezomib inhibits human osteoclastogenesis. (English)

1 reference

9 May 2018

author name string

von Metzler I

1

1 reference

9 May 2018

Krebbel H

2

1 reference

9 May 2018

Hecht M

3

1 reference

9 May 2018

Manz RA

4

1 reference

9 May 2018

Fleissner C

5

1 reference

9 May 2018

Mieth M

6

1 reference

9 May 2018

Kaiser M

7

1 reference

9 May 2018

Jakob C

8

1 reference

9 May 2018

Sterz J

9

1 reference

9 May 2018

Kleeberg L

10

1 reference

9 May 2018

Heider U

11

1 reference

9 May 2018

Sezer O

12

1 reference

9 May 2018

publication date

21 June 2007

1 reference

9 May 2018

published in

Leukemia

1 reference

9 May 2018

volume

21

1 reference

9 May 2018

issue

9

1 reference

9 May 2018

page(s)

2025-2034

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404806

exact match

0 references

cites work

New insights into the pathophysiology and management of bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

RANK ligand and osteoprotegerin in myeloma bone disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Fracture risk with multiple myeloma: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Recombinant LD78 protein, a member of the small cytokine family, enhances osteoclast differentiation in rat bone marrow culture system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Immunocytochemistry reveals RANKL expression of myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

I kappa B: a specific inhibitor of the NF-kappa B transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

The IKK NF-kappa B system: a treasure trove for drug development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

JunB can substitute for Jun in mouse development and cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Degradation of nuclear oncoproteins by the ubiquitin system in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

NF-kappa B as a therapeutic target in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Metastasis to bone: causes, consequences and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Bone resorption by osteoclasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Proteasome as an emerging therapeutic target in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Regulation of c-Jun phosphorylation by the I kappa B kinase-epsilon complex in fibroblast-like synoviocytes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

The IkappaB kinase complex and NF-kappaB act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Expression of VEGF and its receptors by myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404806

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404806

1 reference

9 May 2018

PubMed ID

17581612

1 reference

9 May 2018